# BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors

> **NCT07196111** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Guangzhou Bio-gene Technology Co., Ltd** · enrollment: 12 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia/Lymphoma

## Interventions

- **BIOLOGICAL:** BAFFR CAR-T

## Key facts

- **NCT ID:** NCT07196111
- **Lead sponsor:** Guangzhou Bio-gene Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2028-10-09
- **Final completion:** 2028-12-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07196111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07196111, "BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07196111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*